Business
Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome
STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) (\"Acurx\" or the \"Company\") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that it has filed a provisional patent application in the United States Patent and Trademark Office (USPTO). The filing of this patent application relates to ibezapolstat and its use to treat C. difficile Infection while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials. Acurx is commencing a Phase 2b clinical trial in patients with CDI (Clostridioides difficile Infection) during the second half of this year after having recently completed a Ph2a clinical trial which demonstrated that 10 of 10 patients with CDI (100%) met the study's primary and secondary efficacy endpoints of Clinical Cure at end of treatment and Sustained Clinical Cure with no recurrence of CDI at the 28-day follow-up visit.\nAcurx continues to pursue protection for its technologies in the United States and internationally. Acurx aims to protect the technology, inventions, know-how, and improvements that are important to the development of its business using the most effective intellectual property instruments.\nRobert J. DeLuccia, Executive Chairman of Acurx, stated \"We believe that ibezapolstat's Gram-Positive Selective Spectrum (GPSS™), kills C. difficile, but not other Firmicutes necessary for maintaining a healthy microbiome, and it spares the important Actinobacteria phylum needed for maintaining a healthy microbiome.\" He further stated: \"This concept of a dual-effect treatment which includes bactericidal activity against C. difficile bacteria while at the same time providing a restorative effect on the microbiome has the potential to position ibezapolstat as an important first-line therapy for CDI.\"\nDavid P. Luci, President & CEO of Acurx, stated: \"We believe ibezapolstat's dual effect to effectively treat patients with CDI while simultaneously and dramatically reducing the likelihood of recurrence by restoring the microbiome would be a significant therapeutic advance. This dual effect would subs...